Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

• Status: Completed
• Trial end date: 2021-08-24
• Target enrollment: 0
• Participant gender: All

Summary

This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died or lost to follow-up. To analyze the difference in efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for colorectal cancer, so as to find a better postoperative adjuvant treatment model.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang University
• Treatments: Capecitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Carcinoma of the intestine confirmed histologically or cytologically

• Radical surgical resection was performed after diagnosis and the post operative stages were high-risk II or III patients

• The ECOG PS score less than or equal to 2 points

• No chemotherapy of any kind has been performed in the past

• Neutrophils acuity 1.5x10e9/L, platelets more than 100x10e9/L, college blood red protein more than 9g/dL

• liver function transaminase is less than or equal to 2.5 ULN, alkaline phosphatase is less than 2.5 ULN, and total bilirubin is less than 1.5 ULN

Exclusion Criteria:

• Patients with unresectable CRC

• Patients who have any form of chemotherapy before

• Participating in or having participated in clinical studies of other drug

• Patients have second primary malignant tumors of have other malignant tumors in the past five years

• There is evidence of allergic reaction to drugs in this study

• A history of ischemic heart disease in the past 1 year or patients with high risk factors for heart failure, or uncontrolled arrhythmias

• Severe active inflammation, including tuberculosis and HIV

• Long-term immunization or hormone therapy, except hormone replacement therapy at physiological dose

• Drug or alcohol addiction

• Get pregnant or breastfeed

• The investigator considers that the patient is not suitable for this clinical study due to any clinical or laboratory abnormalities or compliance problems